Treatment of in vitro generated Langerhans cells with JAK-STAT inhibitor reduces their inflammatory potential.
Alopecia areata
Diphencyprone
Interferon gamma
JAK-STAT inhibitor
Langerhans cells
UV-B
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
18
06
2022
accepted:
15
09
2022
medline:
23
10
2023
pubmed:
26
10
2022
entrez:
25
10
2022
Statut:
ppublish
Résumé
Alopecia areata (AA) is a condition in which hair is lost in small regions or over the entire body. It has a prevalence of 1 in 1000 and has a great impact on psychological wellbeing. AA is generally considered an autoimmune disease in which a collapse of the immune privilege system of the hair follicle has shown to play an important role, potentially driven by interferon gamma (IFN-γ). The most prominent cells located in or around the hair follicle in AA are Langerhans cells, CD4
Identifiants
pubmed: 36282458
doi: 10.1007/s10238-022-00899-w
pii: 10.1007/s10238-022-00899-w
doi:
Substances chimiques
Janus Kinase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2571-2582Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Villasante FAC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397–403.
Hordinsky MK. Overview of alopecia areata. J Investig Dermatol Symp Proc. 2013;16(1):S13–5.
pubmed: 24326541
Majid I, Keen MA. Alopecia areata: an update. Br J Med Pract. 2012;5(3):880.
Chelidze K, Lipner SR. Nail changes in alopecia areata: an update and review. Int J Dermatol. 2018;57(7):776–83.
pubmed: 29318582
Rodgers AR. Why finding a treatment for Alopecia Areata is important: a multifaceted perspective. J Investig Dermatol Symp Proc. 2018;19(1):S51-s53.
pubmed: 29273107
Hunt N, McHale S. The psychological impact of alopecia. BMJ (Clinical research ed). 2005;331(7522):951–3.
pubmed: 16239692
Azzawi S, Penzi LR, Senna MM. Immune privilege collapse and alopecia development: is stress a factor. Skin Appendage Disord. 2018;4(4):236–44.
pubmed: 30410890
Biran R, Zlotogorski A, Ramot Y. The genetics of alopecia areata: new approaches, new findings, new treatments. J Dermatol Sci. 2015;78(1):11–20.
pubmed: 25676427
Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med. 1993;66(6):541–54.
pubmed: 7716973
pmcid: 2588848
Paus R, et al. The hair follicle and immune privilege. J Invest Dermatol Symp Proc. 2003;8(2):188–94.
Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol. 2006;7(4):354–9.
pubmed: 16550198
Cotsarelis G, Sun TT, Lavker RM. Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell. 1990;61(7):1329–37.
pubmed: 2364430
Mitchell AJ, Krull EA. Alopecia areata: pathogenesis and treatment. J Am Acad Dermatol. 1984;11(5):763–75.
pubmed: 6210311
Whiting DA. The histopathology of alopecia areata in vertical and horizontal sections. Dermatol Ther. 2001;14(4):297–305.
Ito T, et al. CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase. J Dermatol Sci. 2013;69(2):140–7.
pubmed: 23312578
Zhang X, et al. Lesional infiltration of mast cells, langerhans cells, T cells and local cytokine profiles in alopecia areata. Arch Dermatol Res. 2015;307(4):319–31.
pubmed: 25638328
Sterkens A, Lambert J, Bervoets A. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med. 2021;2:6668.
Flórez-Grau G, et al. Tolerogenic dendritic cells as a promising antigen-specific therapy in the treatment of multiple sclerosis and neuromyelitis optica from preclinical to clinical trials. Front Immunol. 2018;9(1169):9004.
Chung CYJ, et al. Dendritic cells: cellular mediators for immunological tolerance. Clin Dev Immunol. 2013;2013:972865.
pubmed: 23762100
pmcid: 3671285
Cannon MJ, et al. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. Immunotherapy. 2019;11(2):75–9.
pubmed: 30730268
Caux C, et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med. 1996;184(2):695–706.
pubmed: 8760823
Jaatinen T, Laine J. Isolation of mononuclear cells from human cord blood by Ficoll-Paque density gradient. Curr Protoc Stem Cell Biol. 2007;2:50098.
Geissmann F, et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol. 1999;162(8):4567–75.
pubmed: 10201996
Geissmann F, et al. Transforming growth factor beta1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J Exp Med. 1998;187(6):961–6.
pubmed: 9500798
pmcid: 2212193
Picarda G, et al. Functional Langerin high-expressing Langerhans-like cells can arise from CD14-high CD16-human blood monocytes in serum-free condition. J Immunol. 2016;196(9):3716–28.
pubmed: 27016604
Geissmann F, et al. Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med. 2002;196(4):417–30.
pubmed: 12186835
pmcid: 2196053
Takayama K, et al. IL-4 inhibits the migration of human Langerhans cells through the downregulation of TNF receptor II expression. J Invest Drmatol. 1999;113(4):541–6.
Nguyen VA, et al. CD34+ -derived Langerhans cell-like cells are different from epidermal Langerhans cells in their response to thymic stromal lymphopoietin. J Cell Mol Med. 2011;15(9):1847–56.
pubmed: 21054781
pmcid: 3918041
Hoath SB, Leahy DG. The organization of human epidermis: functional epidermal units and phi proportionality. J Invest Dermatol. 2003;121(6):1440–6.
pubmed: 14675195
Strunk D, et al. Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood. 1996;87:1292–302.
pubmed: 8608217
Borkowski TA, et al. A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J Exp Med. 1996;184(6):2417–22.
pubmed: 8976197
pmcid: 2196398
Lichtman MK, Otero-Vinas M, Falanga V. Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis. Wound Repair Regen. 2016;24(2):215–22.
pubmed: 26704519
Kaplan DH, et al. Autocrine/paracrine TGFbeta1 is required for the development of epidermal Langerhans cells. J Exp Med. 2007;204(11):2545–52.
pubmed: 17938236
pmcid: 2118472
Ebner S, et al. Expression of C-type lectin receptors by subsets of dendritic cells in human skin. Int Immunol. 2004;16(6):877–87.
pubmed: 15113774
Fehres CM, et al. In situ delivery of antigen to DC-SIGN(+)CD14(+) dermal dendritic cells results in enhanced CD8(+) T-cell responses. J Invest Dermatol. 2015;135(9):2228–36.
pubmed: 25885805
Steinman RM, et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 2000;191(3):411–6.
pubmed: 10662786
pmcid: 2195815
Romani N, et al. Langerhans cells dendritic cells of the epidermis. APMIS. 2003;111(7):725–40.
pubmed: 12974775
Streilein JW, Grammer SF. In vitro evidence that Langerhans cells can adopt two functionally distinct forms capable of antigen presentation to T lymphocytes. J Immunol. 1989;143(12):3925.
pubmed: 2592763
Cools N, et al. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol. 2007;82(6):1365–74.
pubmed: 17711977
Cools N, et al. Regulatory T cells and human disease. Clin Dev Immunol. 2007;2007:89195.
pubmed: 18317534
Kimber I, et al. Classification of contact allergens according to potency: proposals. Food Chem Toxicol. 2003;41(12):1799–809.
pubmed: 14563405
Land WG. The role of damage-associated molecular patterns in human diseases: part I-promoting inflammation and immunity. Sultan Qaboos Univ Med J. 2015;15(1):e9–21.
pubmed: 25685392
pmcid: 4318613
Wang EHC, et al. Identification of autoantigen epitopes in Alopecia Areata. J Invest Dermatol. 2016;136(8):1617–26.
pubmed: 27094591
Jux B, Kadow S, Esser C. Langerhans cell maturation and contact hypersensitivity are impaired in aryl hydrocarbon receptor-null mice. J Immunol. 2009;182(11):6709–17.
pubmed: 19454665
Heufler C, Koch F, Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med. 1988;167(2):700–5.
pubmed: 3279156
Peiser M, Wanner R, Kolde G. Human epidermal Langerhans cells differ from monocyte-derived Langerhans cells in CD80 expression and in secretion of IL-12 after CD40 cross-linking. J Leukoc Biol. 2004;76(3):616–22.
pubmed: 15178702
Picker LJ, et al. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature. 1991;349(6312):796–9.
pubmed: 1705666
Sernicola A, et al. Targeting the cutaneous lymphocyte antigen (CLA) in inflammatory and neoplastic skin conditions. Expert Opin Biol Ther. 2020;20(3):275–82.
pubmed: 31951753
Yasaka N, Furue M, Tamaki K. Expression of cutaneous lymphocyte-associated antigen defined by monoclonal antibody HECA-452 on human Langerhans cells. J Dermatol Sci. 1996;11(1):19–27.
pubmed: 8867763
Kubo S, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73(12):2192–8.
pubmed: 24013646
Azuma M, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366(6450):76–9.
pubmed: 7694153
Inaba K, et al. The tissue distribution of the B7–2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med. 1994;180(5):1849–60.
pubmed: 7525841
Inaba K, et al. Expression of B7 costimulator molecules on mouse dendritic cells. Adv Exp Med Biol. 1995;378:65–70.
pubmed: 8526146
Freeman GJ, et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med. 1991;174(3):625–31.
pubmed: 1714935
Freeman GJ, et al. Cloning of B7–2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993;262(5135):909–11.
pubmed: 7694363
Borriello F, et al. B7–1 and B7–2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity. 1997;6(3):303–13.
pubmed: 9075931
Sharpe AH. Analysis of lymphocyte costimulation in vivo using transgenic and “knockout” mice. Curr Opin Immunol. 1995;7(3):389–95.
pubmed: 7546405
Reise SC. Dendritic cells in a mature age. Nat Rev Immunol. 2006;6(6):476–83.
Kryczanowsky F, et al. IL-10-modulated human dendritic cells for clinical use: identification of a stable and migratory subset with improved tolerogenic activity. J Immunol. 2016;197(9):3607–17.
pubmed: 27683749
Yamazaki S, et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med. 2003;198(2):235–47.
pubmed: 12874257
pmcid: 2194081
Freyschmidt-Paul P, et al. Interferon-gamma-deficient mice are resistant to the development of alopecia areata. Br J Dermatol. 2006;155(3):515–21.
pubmed: 16911275
Bhat P, et al. Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis. 2017;8(6):e2836–e2836.
pubmed: 28569770
pmcid: 5520949
Xing L, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–9.
pubmed: 25129481
pmcid: 4362521
Berekmeri A, et al. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719–30.
pubmed: 30118353
Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988–90.
pubmed: 24940651
Jabbari A, et al. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol. 2016;25(8):642–3.
pubmed: 27119625
pmcid: 4963264
Kennedy Crispin M, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.
pubmed: 27699252
pmcid: 5033755
Mackay-Wiggan J, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790.
pubmed: 27699253
pmcid: 5033756